MYC has been shown to regulate cell cycle progression-driven tumor aggressiveness in gliomas (Sun et al., 2024), aligning with our findings that cell cycle progression-related gene signatures are enriched in patients having high ESURATAG-GS scores (Figure 5B). This evidence concerns the gene MYC and central nervous system cancer.